GlassScriptPhysician profile
Justin P Coco
NPI 1265554729
$5,679.39
in general payments reported to CMS, 2019-2025
33 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $502 · 2021: $695 · 2022: $1,248 · 2023: $679 · 2024: $1,183 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.04 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,041.63 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $565.23 | 2019-2021 | |
| Notal Vision, INC. | $446.77 | 2022 | |
| Bausch & Lomb Americas INC. | $353.72 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Thea Pharma INC. | $309.96 | 2022-2025 | Iyuzeh |
| Glaukos Corporation | $278.74 | 2020-2024 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Iaccess Precision Blade, Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $273.64 | 2020-2024 | Cequa |
| Biotissue Holdings INC. | $256.72 | 2021-2025 | |
| Sight Sciences, INC. | $188.26 | 2019-2024 | Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $174.17 | 2020-2022 | |
| Abbvie INC. | $154.70 | 2023-2025 | Lumigan, Vuity |
| Staar Surgical Company | $154.31 | 2019 | |
| Akorn Operating Company LLC | $143.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $137.86 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $127.03 | 2020-2024 | Tecnis Iol, Tecnis Simplicity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $124.12 | 2024 | Izervay |
| Akorn, INC. | $118.12 | 2019-2020 | |
| Genzyme Corporation | $113.85 | 2019 | |
| Allergan, INC. | $109.76 | 2019-2020 | |
| Ivantis, INC | $92.02 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $84.06 | 2019-2021 | |
| Ocular Therapeutix, INC. | $78.24 | 2021-2025 | Dextenza |
| Rxsight INC | $58.15 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
| Harrow Eye, LLC | $42.52 | 2024 | Vevye |
| Nova Eye, INC. | $40.01 | 2024 | |
| Dompe US, INC. | $36.16 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $33.21 | 2025 | Acthar |
| Oyster Point Pharma, INC. | $32.06 | 2022-2023 | Tyrvaya |
| New World Medical,INC. | $29.31 | 2021-2025 | Streamline, Via360, Kahook Dual Blade |
| Kala Pharmaceuticals, INC. | $21.56 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $20.95 | 2024 | Xdemvy |
| Lensar, INC. | $19.75 | 2025 | Lensar Laser System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Coco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.